Clinical Cancer Research Versailles No Abst Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Patel, P. H.
Right arrow Articles by Motzer, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Patel, P. H.
Right arrow Articles by Motzer, R. J.
Clinical Cancer Research Vol. 12, 7215-7220, December 15, 2006
© 2006 American Association for Cancer Research


Molecular Pathways

Targeting von Hippel-Lindau Pathway in Renal Cell Carcinoma

Premal H. Patel1,2, Rajendrakumar S.V. Chadalavada2, R.S.K. Chaganti1,2 and Robert J. Motzer1

Authors' Affiliations: 1 Department of Medicine and 2 Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, New York

Requests for reprints: Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021. Phone: 646-422-4312; Fax: 212-988-0806; E-mail: motzerr{at}mskcc.org.

Abstract

Inheritance of a defective copy of the von Hippel-Lindau (VHL) gene leads to the most common cause of inherited renal cell carcinoma (RCC). In addition, most patients with sporadic RCC have aberrant VHL. In the absence of VHL, hypoxia-inducible factor {alpha} accumulates, leading to production of several growth factors, including vascular endothelial growth factor and platelet-derived growth factor. We review here the biology of RCC and how a combination of proximal and distal block of VHL/hypoxia-inducible factor {alpha} pathway by novel targeted agents, including sunitinib, sorafenib, bevacizumab, everolimus, and temsirolimus, has led to significant improvements in progression-free survival.




This article has been cited by other articles:


Home page
Cancer Res.Home page
S. S. Singhal, J. Singhal, S. Yadav, M. Sahu, Y. C. Awasthi, and S. Awasthi
RLIP76: A Target for Kidney Cancer Therapy
Cancer Res., May 15, 2009; 69(10): 4244 - 4251.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
E. Arai, S. Ushijima, H. Fujimoto, F. Hosoda, T. Shibata, T. Kondo, S. Yokoi, I. Imoto, J. Inazawa, S. Hirohashi, et al.
Genome-wide DNA methylation profiles in both precancerous conditions and clear cell renal cell carcinomas are correlated with malignant potential and patient outcome
Carcinogenesis, February 1, 2009; 30(2): 214 - 221.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
W. Lam, S. Bussom, and Y.-C. Cheng
Effect of hypoxia on the expression of phosphoglycerate kinase and antitumor activity of troxacitabine and gemcitabine in non-small cell lung carcinoma
Mol. Cancer Ther., February 1, 2009; 8(2): 415 - 423.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
T. E. Hutson, R. A. Figlin, J. G. Kuhn, and R. J. Motzer
Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies
Oncologist, October 1, 2008; 13(10): 1084 - 1096.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
E. Arai, S. Ushijima, H. Tsuda, H. Fujimoto, F. Hosoda, T. Shibata, T. Kondo, I. Imoto, J. Inazawa, S. Hirohashi, et al.
Genetic Clustering of Clear Cell Renal Cell Carcinoma Based on Array-Comparative Genomic Hybridization: Its Association with DNA Methylation Alteration and Patient Outcome
Clin. Cancer Res., September 1, 2008; 14(17): 5531 - 5539.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Signoretti, G. Bratslavsky, F. M. Waldman, V. E. Reuter, J. Haaga, M. Merino, G. V. Thomas, M. R. Pins, T. Libermann, J. Gillespie, et al.
Tissue-Based Research in Kidney Cancer: Current Challenges and Future Directions
Clin. Cancer Res., June 15, 2008; 14(12): 3699 - 3705.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
W. Lam, C.-H. Leung, S. Bussom, and Y.-C. Cheng
The Impact of Hypoxic Treatment on the Expression of Phosphoglycerate Kinase and the Cytotoxicity of Troxacitabine and Gemcitabine
Mol. Pharmacol., September 1, 2007; 72(3): 536 - 544.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.